New clinical guidelines specifically focused on attention-deficit/hyperactivity disorder (ADHD) in adults are nearing publication in the United States, potentially giving healthcare professionals a more consistent framework for recognising, diagnosing and treating a condition that has historically received less attention in adults.
The American Professional Society of ADHD and Related Disorders (APSARD) has been developing the first dedicated U.S. clinical guidelines for adult ADHD. In August 2026, APSARD announced that the guidelines had entered their final review stage, with publication anticipated in fall 2026. 1
The forthcoming guidelines are expected to address several areas of adult ADHD care, including screening and diagnosis, pharmacological treatment, psychosocial and other non-medication interventions, and assessment of coexisting conditions.
Why Are New Adult ADHD Guidelines Needed?
ADHD is often associated with childhood, but symptoms can persist into adulthood. They may also look different as people get older and can affect work, relationships, organisation, time management and other areas of daily life.
The U.S. Centers for Disease Control and Prevention notes that ADHD begins during childhood and can continue into adulthood, while symptoms and their impact may change across the lifespan. Some adults may reach adulthood without ever receiving a diagnosis. 2
APSARD says there are currently no dedicated U.S. clinical practice guidelines addressing the diagnosis and treatment of ADHD specifically in adults. The organisation developed its guidelines to help address that gap and provide evidence-informed recommendations for clinicians, patients and other stakeholders. 3
What Will The New Adult ADHD Guidelines Cover?
The guidelines are being developed around three major areas of adult ADHD care.
- Screening and diagnosis: How clinicians should identify possible ADHD and conduct an appropriate diagnostic assessment.
- Pharmacological treatment: Evidence-based recommendations concerning medication treatment for adults with ADHD.
- Psychosocial and non-medical interventions: Guidance on approaches that can be used alongside or, in some circumstances, instead of medication.
The development process has involved multidisciplinary experts, literature reviews, assessment of existing international guidelines and consideration of the benefits and potential harms of different care options. APSARD has also incorporated perspectives from people with lived experience. 4
Adult ADHD Diagnosis May Receive Greater Attention
One of the most important areas likely to be addressed is diagnosis.
Adult ADHD cannot be diagnosed using a single laboratory test, brain scan or other standalone medical test. A clinical assessment typically considers symptoms, their developmental history and their impact on everyday functioning.
The CDC notes that clinicians assessing adults may determine whether ADHD symptoms were present before age 12 and may seek information from family members or other people who know the individual. Healthcare professionals may also need to consider other conditions that can produce similar symptoms or commonly occur alongside ADHD, including anxiety, depression, sleep problems, substance misuse and learning difficulties. 5
This makes adult ADHD assessment more complex than simply checking whether someone currently experiences difficulties with attention or organisation.
Why Comorbid Conditions Matter
Adults seeking an ADHD assessment may have other physical or mental health conditions at the same time. Symptoms such as difficulty concentrating, forgetfulness, poor sleep or problems with motivation can occur in several conditions.
A comprehensive assessment can therefore help distinguish ADHD from other explanations while also identifying conditions that may require treatment.
The forthcoming APSARD guidelines are expected to provide clearer recommendations around this broader clinical assessment, according to reporting on the guideline development process. 6
What Could The Guidelines Mean For ADHD Treatment?
Medication is one part of adult ADHD treatment, but it is not the only form of support.
Existing international guidance already recognises both pharmacological and non-pharmacological approaches. For example, NICE recommends medication for adults whose ADHD symptoms continue to cause significant impairment after environmental modifications have been considered, while structured psychological interventions can be used for people who do not take medication, cannot tolerate it or continue to experience significant impairment. 7
The new U.S. guidelines could provide a more specifically American, evidence-based framework for making these decisions in adults.
That does not necessarily mean every adult with ADHD will receive medication. Treatment decisions need to take into account symptoms, functional impairment, medical history, preferences, potential adverse effects and other individual circumstances.
Non-Medication Strategies Are Also Expected To Feature
Adult ADHD management can involve strategies designed to improve organisation, planning, time management and coping with symptoms.
Psychological interventions, including forms of cognitive behavioural therapy, have been studied in adults with ADHD. Depending on the individual’s needs, practical environmental changes may also be useful, such as modifying work routines, reducing distractions and using reminders or organisational systems.
The forthcoming guidelines are expected to clarify where psychosocial and other non-medical interventions fit within comprehensive adult ADHD care. 8
Will The Guidelines Change How ADHD Is Diagnosed?
It is too early to say exactly how clinical practice will change because the final recommendations have not yet been published.
However, APSARD has indicated that one objective is to improve consistency in adult ADHD assessment and treatment. The organisation has also identified limited clinician training and disparities in access to care as challenges affecting adult ADHD diagnosis and management. 9
The guidelines are therefore expected to offer practical recommendations rather than simply redefine ADHD.
Adult ADHD Is Not Simply Childhood ADHD In Older People
ADHD is a neurodevelopmental condition that begins during childhood, but its presentation can change over time.
For some adults, overt hyperactivity may become less obvious, while difficulties with attention, organisation, impulsivity, time management or executive functioning can continue to interfere with daily life.
The CDC notes that adult ADHD symptoms may look different from those seen in children and that support and treatment needs can also differ between adults and children. 10
This is one reason adult-specific guidance is important rather than simply applying childhood recommendations to an older population.
What About Existing ADHD Guidelines?
The United States is not without any ADHD treatment guidance. Existing recommendations and clinical resources address ADHD in various age groups or provide information based on professional consensus.
Other countries and international organisations also have established adult ADHD guidance. For example, NICE’s ADHD guideline covers children, young people and adults and includes recommendations for adult diagnosis and treatment. 11
The significance of the APSARD project is that it is designed specifically to establish comprehensive U.S. clinical guidance for adults with ADHD.
Why The Timing Matters
The new guidelines are arriving as adult ADHD has received increasing attention from clinicians, researchers and the public.
More adults are seeking assessments, while clinicians are dealing with questions about diagnosis, treatment choices, medication access and the management of ADHD alongside other conditions.
A standardised evidence-informed framework could help clinicians approach these questions more consistently. APSARD has also indicated plans to make guideline materials available at different levels of detail and develop educational resources for healthcare professionals. 12
What Patients Should Know Right Now
People who suspect they may have ADHD should not wait for the new guidelines before seeking professional assessment if symptoms are significantly affecting their lives.
A diagnosis requires a clinical evaluation. Current CDC information recommends discussing concerns with a healthcare provider, who may conduct an assessment or refer the person to an appropriate mental-health professional. 13
People already receiving ADHD treatment should also not change or stop prescription medication solely because new guidelines are expected. Treatment decisions should be discussed with the clinician managing their care.
What Happens Next?
APSARD’s guidelines have reached their final review stage. According to the organisation, the process has involved successive rounds of expert review and feedback, with the final manuscript to be completed before publication. The organisation anticipates publication in fall 2026. 14
The final recommendations will be important because they will show precisely what APSARD concludes from the available evidence and how those conclusions should be translated into clinical practice.
Key Takeaways
- APSARD is preparing the first dedicated U.S. clinical guidelines for adult ADHD.
- The guidelines entered their final review stage in August 2026.
- Publication is anticipated in fall 2026.
- The recommendations are expected to address screening, diagnosis, medication and psychosocial or non-medication interventions.
- Comorbid conditions and patient perspectives are also part of the guideline-development process.
- ADHD symptoms can persist into adulthood and may present differently from childhood.
- A proper adult ADHD diagnosis requires a clinical assessment rather than a single test.
- The final guidelines could provide greater consistency for adult ADHD care in the United States.
Bottom Line
New U.S. guidelines for adult ADHD are nearing publication and could provide clinicians with a clearer, evidence-informed framework for diagnosis and treatment. APSARD’s guidelines are expected to cover screening and diagnosis, medication, psychosocial interventions and the assessment of coexisting conditions.
The final recommendations have not yet been published, so specific changes to clinical practice cannot be assumed in advance. For now, the development of dedicated adult ADHD guidance represents an effort to address gaps in consistent adult assessment and care while recognising that treatment needs vary from person to person.
For breaking news and live news updates, like us on Facebook or follow us on Twitter and Instagram. Read more on Latest Health on thefoxdaily.com.
COMMENTS 0